My experience interacting with Novo Nordisk is that, in their case, this model has led to massive inefficiencies.
The non-profit aspect has led to lots of internal politics and rigged hires. They are much more inefficient than a classical pharma.
Smells like tax evasion, but what do i know. Isn't IKEAs founder one of the richest people in Swiss?
Novo Nordisk might return to a more realistic market cap once other GLP-1 agonists enter the market, e.g. Lilly's.
My experience interacting with Novo Nordisk is that, in their case, this model has led to massive inefficiencies.
The non-profit aspect has led to lots of internal politics and rigged hires. They are much more inefficient than a classical pharma.